NasdaqCM:POAI

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Predictive Oncology Inc. provides various healthcare products and services primarily in the United States. More Details


Snowflake Analysis

Mediocre balance sheet and overvalued.


Similar Companies

Share Price & News

How has Predictive Oncology's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: POAI's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

0.1%

POAI

-1.7%

US Medical Equipment

-0.8%

US Market


1 Year Return

-83.1%

POAI

16.5%

US Medical Equipment

13.8%

US Market

Return vs Industry: POAI underperformed the US Medical Equipment industry which returned 16.5% over the past year.

Return vs Market: POAI underperformed the US Market which returned 13.8% over the past year.


Shareholder returns

POAIIndustryMarket
7 Day0.1%-1.7%-0.8%
30 Day-24.2%-3.5%-5.7%
90 Day-47.8%12.2%8.6%
1 Year-83.1%-83.1%17.5%16.5%16.4%13.8%
3 Year-94.3%-94.3%70.0%65.6%36.9%27.8%
5 Year-99.9%-99.9%139.5%121.3%85.0%64.2%

Price Volatility Vs. Market

How volatile is Predictive Oncology's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Predictive Oncology undervalued compared to its fair value and its price relative to the market?

0.97x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate POAI's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate POAI's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: POAI is unprofitable, so we can't compare its PE Ratio to the US Medical Equipment industry average.

PE vs Market: POAI is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate POAI's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: POAI is good value based on its PB Ratio (1x) compared to the US Medical Equipment industry average (3.9x).


Next Steps

Future Growth

How is Predictive Oncology forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

24.4%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Predictive Oncology has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Predictive Oncology performed over the past 5 years?

-30.0%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: POAI is currently unprofitable.

Growing Profit Margin: POAI is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: POAI is unprofitable, and losses have increased over the past 5 years at a rate of 30% per year.

Accelerating Growth: Unable to compare POAI's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: POAI is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (1.8%).


Return on Equity

High ROE: POAI has a negative Return on Equity (-219.56%), as it is currently unprofitable.


Next Steps

Financial Health

How is Predictive Oncology's financial position?


Financial Position Analysis

Short Term Liabilities: POAI's short term assets ($4.3M) do not cover its short term liabilities ($14.7M).

Long Term Liabilities: POAI's short term assets ($4.3M) exceed its long term liabilities ($1.2M).


Debt to Equity History and Analysis

Debt Level: POAI's debt to equity ratio (37.7%) is considered satisfactory.

Reducing Debt: POAI had negative shareholder equity 5 years ago, but is now positive and has therefore improved.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: POAI has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: POAI has less than a year of cash runway if free cash flow continues to reduce at historical rates of 13.2% each year


Next Steps

Dividend

What is Predictive Oncology current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate POAI's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate POAI's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if POAI's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if POAI's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of POAI's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.8yrs

Average management tenure


CEO

Carl Schwartz (79 yo)

3.75yrs

Tenure

US$476,600

Compensation

Dr. Carl I. Schwartz has been Chief Executive Officer of Predictive Oncology Inc. (formerly known as Precision Therapeutics Inc.) (formerly known as Skyline Medical Inc.) since December 1, 2016. Dr. Schwar ...


CEO Compensation Analysis

Compensation vs Market: Carl's total compensation ($USD476.60K) is about average for companies of similar size in the US market ($USD604.44K).

Compensation vs Earnings: Carl's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Carl Schwartz
CEO & Director3.75yrsUS$476.60k10.45%
$ 1.4m
Robert Myers
CFO & Secretary8.17yrsUS$371.43k0.00050%
$ 66.0
Kevin Hungerford
Vice President of Sales & Marketing2.5yrsno datano data

3.8yrs

Average Tenure

Experienced Management: POAI's management team is considered experienced (3.8 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Carl Schwartz
CEO & Director3.75yrsUS$476.60k10.45%
$ 1.4m
Paul Kornblith
Member of Medical Advisory Board2yrsno datano data
J. Engle
Independent Chairman of the Board0.67yrUS$116.87k0.026%
$ 3.5k
Hector Gomez
Member of Medical Advisory Board1.92yrsno datano data
Paul Sweetnam
Member of Scientific Advisory Board4yrsno datano data
Charles Nuzum
Director0.17yrno datano data
Tony Frudakis
Member of Scientific Advisory Board1.83yrsno datano data
Richard Gabriel
Director3.75yrsUS$100.36k0.078%
$ 10.3k
Marc Malandro
Member of Scientific Advisory Board2yrsno datano data
Amelia Warner
Member of Scientific Advisory Board2yrsno datano data
Robert Murphy
Member of Scientific Advisory Board2yrsno datano data
Ratmir Derda
Member of Scientific Advisory Board1.83yrsno datano data

2.0yrs

Average Tenure

71yo

Average Age

Experienced Board: POAI's board of directors are not considered experienced ( 2 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: POAI insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 393.3%.


Top Shareholders

Company Information

Predictive Oncology Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Predictive Oncology Inc.
  • Ticker: POAI
  • Exchange: NasdaqCM
  • Founded: 2002
  • Industry: Health Care Supplies
  • Sector: Healthcare
  • Market Cap: US$13.200m
  • Shares outstanding: 15.42m
  • Website: https://www.predictive-oncology.com

Number of Employees


Location

  • Predictive Oncology Inc.
  • 2915 Commers Drive
  • Suite 900
  • Eagan
  • Minnesota
  • 55121
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
POAINasdaqCM (Nasdaq Capital Market)YesCommon StockUSUSDNov 2009
S1K2DB (Deutsche Boerse AG)YesCommon StockDEEURNov 2009

Biography

Predictive Oncology Inc. provides various healthcare products and services primarily in the United States. The company operates in three segments: Domestic, International, and Helomics. The company manufac ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/09/28 05:41
End of Day Share Price2020/09/25 00:00
Earnings2020/06/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.